4-[(2-Amino-2-Oxoethyl)(Methyl)carbamoyl]-2-Phenyl-1h-Imidazole-5-Carboxylic Acid | 1258599-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[(2-Amino-2-Oxoethyl)(Methyl)carbamoyl]-2-Phenyl-1h-Imidazole-5-Carboxylic Acid
• 英文别名: 4-[(2-amino-2-oxoethyl)-methylcarbamoyl]-2-phenyl-1H-imidazole-5-carboxylic acid
• CAS: 1258599-96-0
• 化学式: C₁₄H₁₄N₄O₄
• 分子量: 302.29
• InChiKey: IKAWXRIWROBKBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(甲基氨基)乙酰胺 、 5,10-dioxo-3,8-diphenyl-5H,10H-diimidazo[1,5-a:1',5'-d]pyrazine-1,6-dicarbonyl dichloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-[(2-Amino-2-Oxoethyl)(Methyl)carbamoyl]-2-Phenyl-1h-Imidazole-5-Carboxylic Acid
  参考文献：
  名称：

  Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution

  摘要：

  Pin1 is an emerging oncology target strongly implicated in Ras and ErbB2-mediated tumourigenesis. Pin1 isomerizes bonds linking phospho-serine/threonine moieties to proline enabling it to play a key role in proline-directed kinase signalling. Here we report a novel series of Pin1 inhibitors based on a phenyl imidazole acid core that contains sub-mu M inhibitors. Compounds have been identified that block prostate cancer cell growth under conditions where Pin1 is essential. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.063

文献信息

• [EN] PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF<br/>[FR] COMPOSITIONS ET COMBINAISONS PHARMACEUTIQUES COMPRENANT DES INHIBITEURS DU RÉCEPTEUR DES ANDROGÈNES ET UTILISATIONS DE CELLES-CI
  申请人：ESSA PHARMA INC

  公开号：WO2020198712A1

  公开（公告）日：2020-10-01

  The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combintaions useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.

  本公开涉及药物组合和制剂，包括雄激素受体N端域抑制剂或抑制剂和第二种治疗活性剂，例如CDK4/6抑制剂、Pin1抑制剂（肽前脯氨酸顺反异构酶抑制剂）或抗雄激素。特别地，本公开涉及用于治疗各种癌症的药物组合和制剂，例如乳腺癌和前列腺癌。此外，本公开还涉及将雄激素受体N端域抑制剂与放射治疗联合使用以治疗各种癌症。
• PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF
  申请人：ESSA Pharma, Inc.

  公开号：US20220218632A1

  公开（公告）日：2022-07-14

  The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.